FOI 7409 - NSCLC patients treated with various drugs

Date: 17 June 2022 to 17 June 2025

I have a freedom of information query. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

  • Afatinib
  • Alectinib
  • Amivantamab
  • Atezolizumab monotherapy
  • Atezolizumab with chemotherapy
  • Brigatinib
  • Ceritinib
  • Crizotinib
  • Dacomitinib
  • Dabrafenib with Trametinib
  • Durvalumab
  • Erlotinib
  • Gefitinib
  • Lorlatinib
  • Mobocertinib
  • Nintedanib with Docetaxel
  • Nivolumab
  • Osimertinib
  • Pembrolizumab monotherapy
  • Pembrolizumab with chemotherapy
  • Pemetrexed with Carboplatin/Cisplatin
  • Sotorasib
  • Tepotinib
  • Vinorelbine with Carboplatin/Cisplatin
  • Any other active systemic anti-cancer therapy (SACT)
  • Palliative care only
  • Request ID:
    7409
  • Category:
    Patient - Activity Data
  • Response:

    June 2022

    Freedom of Information Request: reference 7409

     

    Thank you for your recent request under the Freedom of Information Act 2000.

     

    The information you have requested is as follows:

     

    I have a freedom of information query. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

    • Afatinib
    • Alectinib
    • Amivantamab
    • Atezolizumab monotherapy
    • Atezolizumab with chemotherapy
    • Brigatinib
    • Ceritinib
    • Crizotinib
    • Dacomitinib
    • Dabrafenib with Trametinib
    • Durvalumab
    • Erlotinib
    • Gefitinib
    • Lorlatinib
    • Mobocertinib
    • Nintedanib with Docetaxel
    • Nivolumab
    • Osimertinib
    • Pembrolizumab monotherapy
    • Pembrolizumab with chemotherapy
    • Pemetrexed with Carboplatin/Cisplatin
    • Sotorasib
    • Tepotinib
    • Vinorelbine with Carboplatin/Cisplatin
    • Any other active systemic anti-cancer therapy (SACT)
    • Palliative care only

     

    Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated. 

    The Trust’s Business Intelligence team collate patient numbers for medical conditions, but do not collate data around the treatments patients receive.

    Therefore, we can confirm that from 01/03/2022 to 13/06/2022, there were a total of 116 lung cancer patients treated by the Trust, however, coding does not distinguish which of these patients are ‘non-small cell’.

    The Trust’s Pharmacy team collate data relating to drugs issued but do not record the indication for the use of the drug or whether it was administered to the patient.  Please see below data held for all drugs from BNF chapter 8 – Immune System + Malignant Disease, for any indication not just NSCLC.  If the drug is not listed it is because it hasn’t been issued from Pharmacy.   . 

     

    Patient Count of Medication Issued from Pharmacy
    between 14/03/2022 to 13/06/2022

    Drug

    Number of Patients

    ABEMACICLIB (VERZENIOS)

    <5

    ABIRATERONE

    15

    ABIRATERONE (ZYTIGA) - HOMECARE

    7

    ACALABRUTINIB (CALQUENCE)

    <5

    ACALABRUTINIB (CALQUENCE) - HOMECARE

    16

    AFATINIB (ORAL)

    <5

    ANASTROZOLE (ORAL)

    <5

    APALUTIMIDE (ERLEADA)

    6

    ATEZOLIZUMAB (TECENTRIQ)

    11

    AVELUMAB (BAVENCIO)

    6

    AXITINIB

    <5

    AXITINIB (ORAL)

    7

    AZACITIDINE

    16

    AZATHIOPRINE

    22

    BCG FOR INTRADERMAL USE

    <5

    BCG FOR INTRAVESICAL USE (OncoTICE)

    46

    BENDAMUSTINE

    <5

    BICALUTAMIDE

    19

    BLEOMYCIN

    <5

    BORTEZOMIB

    21

    BOSUTINIB (BOSULIF) - HOMECARE

    <5

    BRENTUXIMAB

    <5

    CABAZITAXEL

    <5

    CABOZANTINIB

    <5

    CABOZANTINIB (CABOMETYX)

    <5

    CALCIUM FOLINATE (IV)

    58

    CAPECITABINE (ORAL)

    46

    CARBOPLATIN (IV)

    60

    CARFILZOMIB

    <5

    CETUXIMAB

    9

    CHLORAMBUCIL

    <5

    CICLOSPORIN (DEXIMUNE)

    <5

    CICLOSPORIN (NEORAL)

    <5

    CICLOSPORIN (SANDIMMUN)

    <5

    CISPLATIN (IV)

    6

    CYCLOPHOSPHAMIDE (IV)

    80

    CYCLOPHOSPHAMIDE (ORAL)

    <5

    CYTARABINE

    7

    DACARBAZINE

    <5

    DARATUMUMAB (DARZALEX)

    16

    DASATINIB

    <5

    DASATINIB (SPRYCEL) - HOMECARE

    6

    DAUNORUBICIN

    <5

    DEGARELIX

    <5

    DIMETHYL FUMARATE (TECIFIDERA) - HOMECARE

    101

    DIMETHYL SULFOXIDE (DMSO)

    <5

    DOCETAXEL

    31

    DOXORUBICIN

    18

    ENZALUTAMIDE

    41

    ENZALUTAMIDE (XTANDI) - HOMECARE

    21

    EPIRUBICIN

    60

    ERIBULIN

    <5

    ETOPOSIDE

    18

    EVEROLIMUS

    <5

    EXEMESTANE

    6

    FLUDARABINE (IV)

    <5

    FLUOROURACIL

    63

    FULVESTRANT

    12

    GEMCITABINE

    10

    GEMTUZUMAB, OZOGAMICIN, MYLOTARG

    <5

    GILTERITINIB (XOSPATA) - HOMECARE

    <5

    GLATIRAMER ACETATE (COPAXONE) - HOMECARE

    9

    HOMECARE APALUTAMIDE (ERLEADA)

    <5

    HYDROXYCARBAMIDE

    58

    HYDROXYCARBAMIDE - HOMECARE

    <5

    HYDROXYCARBAMIDE (SIKLOS)

    <5

    HYDROXYCARBAMIDE (XROMI)

    <5

    IBRUTINIB

    <5

    IBRUTINIB - HOMECARE

    <5

    IBRUTINIB (IMBRUVICA) - HOMECARE

    13

    IDARUBICIN

    <5

    IDARUBICIN (BATHASU)

    <5

    IDELALISIB (ZYDELIG) - HOMECARE

    <5

    IMATINIB

    <5

    IMATINIB - HOMECARE

    10

    INTERFERON BETA 1A (AVONEX) - HOMECARE

    24

    INTERFERON BETA-1a (REBIF via REBISMART) - HOMECARE

    17

    INTERFERON BETA-1b (BETAFERON 250mcg/ml) - HOMECARE

    <5

    IPILIMUMAB (YERVOY)

    <5

    IRINOTECAN

    34

    ISATUXIMAB (SARCLISA)

    <5

    IXAZOMIB (NINLARO)

    <5

    IXAZOMIB (NINLARO) - HOMECARE

    8

    LENALIDAMIDE - HOMECARE

    41

    LENALIDOMIDE

    9

    LETROZOLE

    58

    LETROZOLE - HOMECARE

    <5

    LEUPRORELIN

    <5

    LORLATINIB (LORVIQUA)

    <5

    MERCAPTOPURINE

    <5

    MESNA

    <5

    METHOTREXATE

    <5

    METHOTREXATE (IV)

    9

    METHOTREXATE (METOJECT PEN)

    16

    METHOTREXATE (METOJECT PEN) - HOMECARE

    236

    METHOTREXATE (ORAL)

    90

    MITOMYCIN

    <5

    MYCOPHENOLATE MOFETIL

    17

    MYCOPHENOLIC ACID (ORAL)

    <5

    NATALIZUMAB

    16

    NILOTINIB (TASIGNA) - HOMECARE

    10

    NINTEDANIB

    <5

    NIVOLUMAB (OPDIVO)

    10

    OBINUTUZUMAB

    12

    OCTREOTIDE

    <5

    OSIMERTINIB

    <5

    OXALIPLATIN (IV)

    54

    PACLITAXEL

    60

    PALBOCICLIB

    39

    PALBOCICLIB (IBRANCE) - HOMECARE

    <5

    PANOBINOSTAT

    <5

    PAZOPANIB

    14

    PEMBROLIZUMAB

    34

    PEMETREXTED

    22

    PERTUZUMAB

    <5

    PERTUZUMAB/TRASTUZUMAB (PHESGO)

    37

    POLATUZUMAB (POLIVY)

    <5

    POMALIDOMIDE

    <5

    POMALIDOMIDE (IMNOVID) - HOMECARE

    <5

    PONATINIB - HOMECARE

    <5

    PROCARBAZINE

    <5

    RALTITREXED

    <5

    RASBURICASE

    <5

    RIBOCICLIB

    <5

    RITUXIMAB (MABTHERA)

    14

    RITUXIMAB (RIXATHON)

    28

    RITUXIMAB (TRUXIMA)

    22

    RUXOLITINIB

    <5

    RUXOLITINIB - HOMECARE

    13

    SUNITINIB

    <5

    TACROLIMUS

    <5

    TACROLIMUS  (ADVAGRAF)

    <5

    TACROLIMUS (ADOPORT)

    <5

    TACROLIMUS (ADVAGRAF)

    <5

    TACROLIMUS (PROGRAF)

    <5

    TACROLIMUS (TOPICAL)

    <5

    TAMOXIFEN

    10

    TERIFLUNOMIDE (AUBAGIO) - HOMECARE

    41

    THALIDOMIDE

    10

    TIPIRACIL/TRIFLURIDINE

    7

    TOPOTECAN

    <5

    TRASTUZUMAB

    <5

    TRASTUZUMAB (HERCEPTIN)

    16

    TRASTUZUMAB (ONTRUZANT)

    <5

    TRASTUZUMAB DERUXTECAN

    8

    TRASTUZUMAB EMTANSINE

    10

    VENETOCLAX

    11

    VENETOCLAX (VENCLYXTO) - HOMECARE

    <5

    VINBLASTINE

    <5

    VINCRISTINE

    38

    VINORELBINE

    9